Technical Analysis for NBTX - Nanobiotix S.A.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 15.66 | -3.21% | -0.52 |
NBTX closed down 0.12 percent on Monday, April 12, 2021, on 8 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Down |
Historical NBTX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -3.21% | |
Narrow Range Bar | Range Contraction | -3.21% | |
NR7 | Range Contraction | -3.21% | |
Weak + Overbought | Other | -3.21% | |
Inside Day | Range Contraction | -3.21% | |
Weak, Overbought and Reversal Signs | Reversal | -3.21% | |
Overbought Stochastic | Strength | -3.21% | |
Fell Below 50 DMA | Bearish | -3.33% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -3.33% | |
Volume Surge | Other | -3.33% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 3% | about 3 hours ago |
Down 2 % | about 3 hours ago |
Down 1% | about 3 hours ago |
Fell Below 20 DMA | about 3 hours ago |
Fell Below 10 DMA | about 3 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/01/2021
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotix’s novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immunotherapy Oncology Cancer Immunotherapy Virotherapy Immunotherapies Radiation Therapy Nanotechnology Nanomedicine Radiotherapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immunotherapy Oncology Cancer Immunotherapy Virotherapy Immunotherapies Radiation Therapy Nanotechnology Nanomedicine Radiotherapy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.55 |
52 Week Low | 12.85 |
Average Volume | 8,122 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 16.63 |
20-Day Moving Average | 15.82 |
10-Day Moving Average | 15.75 |
Average True Range | 0.79 |
ADX | 29.76 |
+DI | 13.96 |
-DI | 26.99 |
Chandelier Exit (Long, 3 ATRs ) | 14.51 |
Chandelier Exit (Short, 3 ATRs ) | 15.22 |
Upper Bollinger Band | 16.86 |
Lower Bollinger Band | 14.78 |
Percent B (%b) | 0.67 |
BandWidth | 13.14 |
MACD Line | -0.13 |
MACD Signal Line | -0.28 |
MACD Histogram | 0.1559 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 16.34 | ||||
Resistance 3 (R3) | 16.36 | 16.32 | 16.31 | ||
Resistance 2 (R2) | 16.32 | 16.28 | 16.31 | 16.30 | |
Resistance 1 (R1) | 16.25 | 16.26 | 16.23 | 16.23 | 16.29 |
Pivot Point | 16.22 | 16.22 | 16.21 | 16.21 | 16.22 |
Support 1 (S1) | 16.15 | 16.17 | 16.13 | 16.13 | 16.07 |
Support 2 (S2) | 16.11 | 16.15 | 16.10 | 16.06 | |
Support 3 (S3) | 16.04 | 16.11 | 16.05 | ||
Support 4 (S4) | 16.02 |